Preclinical In-House Validation of Commercially Available Fluorescence In-Situ Hybridization Probes Used in Diagnosis of Haematological Malignancies

• DOI: 10.31487/j.ejmc.2020.01.01
• Publication Date: 2020-03-31T18:35:15Z
• Authors: Dhanlaxmi Shetty; Dhanlaxmi Shetty; Elizabeth Talker; Hemani Jain
• Keywords: 03 medical and health sciences; 0302 clinical medicine

World Health Organization states the importance of conventional cytogenetics and FISH in hematological malignancy for accurate diagnosis, treatment and monitoring response to therapy. Most FISH probes, however, are Analyte- Specific reagents (not FDA approved) and thus an elaborate validation procedure prior to diagnostic use becomes essential. This study focuses on validating FISH probes by assessing the analyte- sensitivity, specificity, accuracy, precision and determining normal reference ranges (cut-offs). Eight probes from two different manufacturers each were validated using cytogenetically normal peripheral blood (negative controls) and leukemia positive bone marrow samples (positive controls) to determine the most suitable probe for use in a diagnostic set-up. Both the controls were cytogenetically defined before initiating the validation procedure. Alongside this, the probe constructs were studied to understand signal co-localization, size and intensity. Accuracy was determined by metaphase FISH, precision by standard deviation or inter-observer variability and analyte specificity and sensitivity using standard formulae. The cut-off or the normal reference range was derived by BETAINV function in Microsoft Excel. Based on performance characteristics and qualitative data most relevant probes were suggested for diagnostic use. Although validation procedures may differ between test centres, it should be a mandate pre-clinical practice. A validated FISH probe surges dependability on generated reports and this study presents the most rudimentary yet essential parameters in a FISH probe validation.